Topic Hub

Testosterone Cypionate — Regulatory History

4 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.

4articles

25keywords mapped

2026-05-26latest review

Explore

Testosterone Cypionate — Regulatory History library

Showing 4 of 4 clinical reviews.

Safety2026-05-26

Testosterone Cypionate FAERS Safety Signals: What Post-Market Surveillance Data Actually Shows

A clinical breakdown of testosterone cypionate safety signals reported to the FDA Adverse Event Reporting System (FAERS), including cardiovascular events, polycythemia, liver injury, and what the data means for patients on TRT.

Read clinical review

Safety2026-05-25

Testosterone Cypionate Label Updates 2020 to 2026: FDA Safety Warnings, Boxed Warnings, and Post-Market Changes

A complete timeline of FDA label updates for testosterone cypionate from 2020 through 2026, including cardiovascular warnings, abuse potential language, polycythemia alerts, and the impact of the TRAVERSE trial on prescribing.

Read clinical review

Clinical Reviews2026-05-25

Testosterone Cypionate Pipeline and Next-Gen Formulations

A clinical review of testosterone cypionate's regulatory history, FDA label updates, post-market safety data from TRAVERSE, and the next-generation testosterone delivery systems in development.

Read clinical review

Comparisons2026-05-25

Testosterone Cypionate: EMA vs FDA Regulatory Approach

How the FDA and EMA differ in their approval, labeling, and post-market surveillance of testosterone cypionate for hypogonadism and testosterone replacement therapy.

Read clinical review